Medicine guide

Raplixa

·

  • Prescription status not stated
  • Blood, clotting and anaemia
Made by
Mallinckrodt Pharmaceuticals Ireland Limited

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

What it is for

  • Supportive treatment where standard surgical techniques are insufficient for improvement of haemostasis. Raplixa must be used in combination with an approved gelatin sponge. Raplixa is indicated in adults over 18 years of age.

From the official label · 2026-09-30 · European Medicines Agency

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

United StatesNo exact match for this strength and form

SpainNo exact match for this strength and form

CanadaNo exact match for this strength and form

NetherlandsNo exact match for this strength and form

SwitzerlandNo exact match for this strength and form

Details

Made byMallinckrodt Pharmaceuticals Ireland Limited
Active substanceHuman fibrinogen;human thrombin
Used inBlood, clotting and anaemia
ClassificationB02BC30 · Blood, clotting and anaemia
Additional monitoring ▼Yes — under additional monitoring (black triangle). Report suspected side effects.
Authorised on2015-03-19
Last updated by the regulator2018-10-10
EMA product numberEMEA/H/C/002807

Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician

Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.